Sidley represented the underwriters in the upsized US$198.7 million initial public offering by Tyra Biosciences, Inc. (NASDAQ: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. BofA Securities, Jefferies and Cowen acted as joint book-running managers of the offering. Continue reading

See all Member News